JP2012523459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523459A5 JP2012523459A5 JP2012506110A JP2012506110A JP2012523459A5 JP 2012523459 A5 JP2012523459 A5 JP 2012523459A5 JP 2012506110 A JP2012506110 A JP 2012506110A JP 2012506110 A JP2012506110 A JP 2012506110A JP 2012523459 A5 JP2012523459 A5 JP 2012523459A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- independently
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 65
- 125000001072 heteroaryl group Chemical group 0.000 claims 59
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 229910052739 hydrogen Inorganic materials 0.000 claims 57
- 239000001257 hydrogen Substances 0.000 claims 54
- 229910052799 carbon Inorganic materials 0.000 claims 50
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 38
- 125000000304 alkynyl group Chemical group 0.000 claims 38
- 125000003342 alkenyl group Chemical group 0.000 claims 37
- 150000002431 hydrogen Chemical group 0.000 claims 37
- 125000003545 alkoxy group Chemical group 0.000 claims 26
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 20
- -1 isopropoxy, isobutoxy, sec-butoxy, tert-butoxy, 3-methylbutoxy, 2,2-dimethylpropoxy Chemical group 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 14
- 125000002837 carbocyclic group Chemical group 0.000 claims 14
- 125000001153 fluoro group Chemical group F* 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 125000004104 aryloxy group Chemical group 0.000 claims 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000002252 acyl group Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 125000004442 acylamino group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 125000003282 alkyl amino group Chemical group 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims 9
- 125000006239 protecting group Chemical group 0.000 claims 8
- 125000005256 alkoxyacyl group Chemical group 0.000 claims 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims 7
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 7
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000001246 bromo group Chemical group Br* 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 208000030533 eye disease Diseases 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000007970 thio esters Chemical class 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 101150065749 Churc1 gene Proteins 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 102100038239 Protein Churchill Human genes 0.000 claims 4
- 125000005035 acylthio group Chemical group 0.000 claims 4
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 125000005228 aryl sulfonate group Chemical group 0.000 claims 4
- 125000005110 aryl thio group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004437 phosphorous atom Chemical group 0.000 claims 4
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000003441 thioacyl group Chemical group 0.000 claims 4
- 150000003568 thioethers Chemical class 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 3
- 125000001769 aryl amino group Chemical group 0.000 claims 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 3
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 2
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 2
- 229930184725 Lipoxin Natural products 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- KFINXCASWPGHEW-UHFFFAOYSA-N (9S*,10R*,11R*,12Z,15Z)-9,10,11-trihydroxyoctadeca-12,15-dienoic acid Natural products CCC=CCC=CC(O)C(O)C(O)CCCCCCCC(O)=O KFINXCASWPGHEW-UHFFFAOYSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- MZQXAWAWDWCIKG-SPSBLGDNSA-N Avenoleic acid Chemical class CCC[C@@H](O)C\C=C/C\C=C/CCCCCCCC(O)=O MZQXAWAWDWCIKG-SPSBLGDNSA-N 0.000 claims 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 0 CCC#CCC(C)(C1=C*(*)C=CC=C1C=C[C@@](C(CC=CCCN)[O-])[O-])O Chemical compound CCC#CCC(C)(C1=C*(*)C=CC=C1C=C[C@@](C(CC=CCCN)[O-])[O-])O 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16873909P | 2009-04-13 | 2009-04-13 | |
| US61/168,739 | 2009-04-13 | ||
| US17480609P | 2009-05-01 | 2009-05-01 | |
| US61/174,806 | 2009-05-01 | ||
| PCT/US2010/030813 WO2010120719A1 (en) | 2009-04-13 | 2010-04-13 | Compositions and methods for the treatment of inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523459A JP2012523459A (ja) | 2012-10-04 |
| JP2012523459A5 true JP2012523459A5 (https=) | 2013-05-30 |
| JP5785537B2 JP5785537B2 (ja) | 2015-09-30 |
Family
ID=42982804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506110A Expired - Fee Related JP5785537B2 (ja) | 2009-04-13 | 2010-04-13 | 炎症を処置するための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8673881B2 (https=) |
| EP (1) | EP2419399B1 (https=) |
| JP (1) | JP5785537B2 (https=) |
| CN (1) | CN104203901A (https=) |
| AU (1) | AU2010236663B2 (https=) |
| BR (1) | BRPI1011325A2 (https=) |
| CA (1) | CA2758586A1 (https=) |
| CL (1) | CL2011002548A1 (https=) |
| ES (1) | ES2576086T3 (https=) |
| IL (1) | IL215592A (https=) |
| MX (1) | MX2011010827A (https=) |
| NZ (1) | NZ596228A (https=) |
| RU (1) | RU2543720C2 (https=) |
| TW (1) | TW201039815A (https=) |
| WO (1) | WO2010120719A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582785B2 (en) * | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
| US8900626B2 (en) * | 2011-06-20 | 2014-12-02 | Senju Usa, Inc. | Transdermal drug delivery system and method of using the same |
| RU2497498C2 (ru) * | 2012-02-14 | 2013-11-10 | Константин Николаевич Руссков | Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о" |
| WO2014030132A2 (en) | 2012-08-22 | 2014-02-27 | Universidad De Los Andes | Use of statins for periodontal disease and bone regeneration |
| WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
| HK1219654A1 (zh) | 2013-02-22 | 2017-04-13 | University Of Southern California | 用於治疗眼科疾病和病症的方法 |
| WO2016028800A1 (en) * | 2014-08-20 | 2016-02-25 | A.T. Resolve Sarl | Treatment of corneal haze |
| WO2016144569A1 (en) | 2015-03-10 | 2016-09-15 | Elc Management Llc | Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways |
| CN105287480B (zh) * | 2015-10-28 | 2019-01-11 | 西安医学院第一附属医院 | Resolvin D1作为抗癫痫药物的应用 |
| WO2018002930A1 (en) | 2016-06-30 | 2018-01-04 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| EP3624815A4 (en) * | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
| CN107445821A (zh) * | 2017-08-11 | 2017-12-08 | 上海中医药大学 | 聚炔酸类衍生物 |
| CN112955145A (zh) | 2018-09-04 | 2021-06-11 | 密涅瓦神经科学有限公司 | 使用苯氧丙胺化合物治疗疼痛的方法 |
| AU2019463156B2 (en) * | 2019-08-27 | 2024-08-15 | Cellin Technologies Oü | Activated mesenchymal stem cells for treating limb ischemia |
| JP2023504205A (ja) * | 2019-12-09 | 2023-02-01 | ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ | 角膜病変の治療のための生体分子 |
| CN110988180A (zh) * | 2019-12-19 | 2020-04-10 | 山东达因海洋生物制药股份有限公司 | 一种基于杂质谱的埃索美拉唑镁的有关物质分析方法 |
| WO2023250031A1 (en) * | 2022-06-21 | 2023-12-28 | Anida Pharma Inc. | Compositions and methods for treating hearing and ocular disorders |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| DE69839355T2 (de) | 1997-07-29 | 2009-06-04 | Alcon Laboratories, Inc., Fort Worth | Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6831186B2 (en) * | 2001-11-06 | 2004-12-14 | Schering Aktiengesellschft | Lipoxin A4 analogs |
| AU2002349297A1 (en) | 2001-12-03 | 2003-06-17 | Kobenhavns Amt | Statin-like compounds |
| US7582785B2 (en) * | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| CA2699483A1 (en) * | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
| JP5421272B2 (ja) * | 2007-10-12 | 2014-02-19 | リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド | 眼病治療のための組成物及び方法 |
| DE102008027146B4 (de) | 2008-06-02 | 2012-01-19 | Ing. Erich Pfeiffer Gmbh | Austragvorrichtung |
| WO2010039531A1 (en) * | 2008-09-23 | 2010-04-08 | Resolvyx Pharmaceuticals, Inc. | Therapeutic compounds |
| US8619544B2 (en) | 2008-09-23 | 2013-12-31 | Qualcomm Incorporated | Apparatus and method for facilitating transmit diversity for communications |
-
2010
- 2010-03-30 TW TW099109567A patent/TW201039815A/zh unknown
- 2010-04-13 EP EP10764985.7A patent/EP2419399B1/en not_active Not-in-force
- 2010-04-13 WO PCT/US2010/030813 patent/WO2010120719A1/en not_active Ceased
- 2010-04-13 CN CN201080026180.0A patent/CN104203901A/zh active Pending
- 2010-04-13 AU AU2010236663A patent/AU2010236663B2/en not_active Ceased
- 2010-04-13 RU RU2011146005/04A patent/RU2543720C2/ru not_active IP Right Cessation
- 2010-04-13 MX MX2011010827A patent/MX2011010827A/es active IP Right Grant
- 2010-04-13 JP JP2012506110A patent/JP5785537B2/ja not_active Expired - Fee Related
- 2010-04-13 ES ES10764985.7T patent/ES2576086T3/es active Active
- 2010-04-13 BR BRPI1011325A patent/BRPI1011325A2/pt not_active IP Right Cessation
- 2010-04-13 US US13/264,155 patent/US8673881B2/en not_active Expired - Fee Related
- 2010-04-13 NZ NZ596228A patent/NZ596228A/en not_active IP Right Cessation
- 2010-04-13 CA CA2758586A patent/CA2758586A1/en not_active Abandoned
-
2011
- 2011-10-06 IL IL215592A patent/IL215592A/en not_active IP Right Cessation
- 2011-10-13 CL CL2011002548A patent/CL2011002548A1/es unknown
-
2014
- 2014-03-12 US US14/207,342 patent/US9315447B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523459A5 (https=) | ||
| JP7457401B2 (ja) | 毒性アルデヒド関連疾患および処置 | |
| DE60214718T2 (de) | Verbindungen mit taxol-verstärkender wirkung | |
| AU2007275658B2 (en) | Compositions and methods for the treatment of mucositis | |
| JP2016516018A (ja) | パ−キンソン病治療用の新規高透過薬物及びその組成物 | |
| JP2020504728A (ja) | Ｒｎａ送達のためのイオン化可能なカチオン性脂質 | |
| RU2017115925A (ru) | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе | |
| JP2014240429A (ja) | ビニル置換脂肪酸 | |
| RU2012157293A (ru) | Макроциклические соединения, применимые в качестве ингибиторов гистондеацетилаз | |
| JPH08510479A (ja) | 眼の炎症障害を処置するための３‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物 | |
| TW200522978A (en) | Tocopherol-modified therapeutic drug compounds | |
| CN104203901A (zh) | 治疗炎症的组合物和方法 | |
| JP2010539167A (ja) | 免疫機能を調節する組成物および方法 | |
| JP2013528182A5 (https=) | ||
| JP2012507552A (ja) | プロスタグラジンのアミノ酸塩 | |
| EP2635270A1 (en) | Methods of treatment using lipid compounds | |
| CN104640573A (zh) | 萝卜硫烷的分离和纯化 | |
| JP2016536360A5 (https=) | ||
| JP2013536164A5 (https=) | ||
| ES3002189T3 (en) | Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases | |
| JP2019512475A (ja) | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 | |
| JP2011513471A5 (https=) | ||
| JP2024516023A5 (https=) | ||
| RU2011131855A (ru) | Новые оксимовые производные 3,5-секо-4-нор-холестана, фармацевтические композиции, содержащие их, и способ из получения | |
| JP2024041865A (ja) | パ－キンソン病治療用の新規高透過薬物及びその組成物 |